@article{96535e80ee924c8f983fdc7c29886815,
title = "Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology",
abstract = "Introduction: Pyroglutamate-modified amyloid β (AβpE3) could be a biomarker for Aβ plaque pathology in the brain. An ultra-high-sensitive assay is needed for detecting AβpE3-40. Methods: Immunomagnetic reduction was used for quantification of AβpE3-40 in plasma from 46 participants. The concentrations of AβpE3-40 of these subjects were compared with 18F-florbetapir positron emission tomography (PET) images. Results: AβpE3-40 concentration was 44.1 ± 28.2 fg/mL in PET- (n = 28) and 91.6 ± 54.6 fg/mL in PET+ (n = 18; P <.05). The cutoff value of AβpE3-40 for discriminating PET- from PET+ was 55.5 fg/mL, resulting in a sensitivity of 83.3%, a specificity of 71.4%. The concentration of AβpE3-40 showed a moderate correlation (r = 0.437) with PET standardized uptake value ratio. Discussion: We did not enroll pre-clinical AD subject with normal cognition but Aβ PET+. It would be an important issue to explore the feasibility of using AβpE3-40 for screening pre-clinical subjects. Conclusion: These results reveal the feasibility of detecting Aβ pathology using quantification of a plaque-derived Aβ molecule in plasma.",
author = "Wang, {Pei Ning} and Lin, {Kun Ju} and Liu, {Huei Chun} and Ulf Andreasson and Kaj Blennow and Henrik Zetterberg and Yang, {Shieh Yueh}",
note = "Funding Information: Thank you to Paul Weinreb, Fang Qian, and Robert Scannevin at Biogen Inc. for work in developing the antibodies against Aβ. Kaj Blennow holds the Torsten S{\"o}derberg Professorship in Medicine at the Royal Swedish Academy of Sciences, and is supported by the Swedish Research Council (#2017‐00915), the Swedish Alzheimer Foundation (#AF‐742881), Hj{\"a}rnfonden, Sweden (#FO2017‐0243), and a grant (#ALFGBG‐715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‐agreement. pE3‐40 Funding Information: Thank you to Paul Weinreb, Fang Qian, and Robert Scannevin at Biogen Inc. for work in developing the antibodies against A?pE3-40. Kaj Blennow holds the Torsten S?derberg Professorship in Medicine at the Royal Swedish Academy of Sciences, and is supported by the Swedish Research Council (#2017-00915), the Swedish Alzheimer Foundation (#AF-742881), Hj?rnfonden, Sweden (#FO2017-0243), and a grant (#ALFGBG-715986) from the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement. Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of the Alzheimer's Association.",
year = "2020",
doi = "10.1002/dad2.12029",
language = "English",
volume = "12",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}
